Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies…

The Conversation

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

The Independent UK

Eli Lilly is capping consumer insulin costs at $35

Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

US drug maker to slash some insulin prices, expand cost cap

President Joe Biden hails move by Eli Lilly as a ‘big deal’, calling on other manufacturers to also reduce prices.

Al Jazeera

Eli Lilly plans to slash prices of some older insulins, expand cost cap

Lawmakers and patient advocates have been pressuring drugmakers to take action on soaring drug prices.

Chicago Sun-Times

Eli Lilly is capping customers’ insulin costs at $35

Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans.

Tribune News Service

Eli Lily caps the cost of insulin at $35 a month, bringing relief to millions of Americans.

As insulin prices have soared, this manufacturer announces it will reduce costs by 70%.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket

The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live.

WEKU

Under pressure, Eli Lilly cuts insulin prices 70%

Drugmaker Eli Lilly says it's cutting the price of one insulin to below 1990s levels.

Axios

Lilly plans to slash some insulin prices, expand cost cap

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay when they fill prescriptions

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

StockNews.com

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

Tribune News Service

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

StockNews.com

3 Large-Cap Stocks to Add to Your Portfolio Now

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

ABC News

Pharmaceutical giant Eli Lilly & Co apologises after fake Twitter account says insulin is free as Elon Musk rolls back verification

The incident is among a wave of impersonations that prompted Twitter to make its relaunched premium service unavailable.

Fortune

No, insulin is not free: Eli Lilly is the latest high-profile casualty of Elon Musk’s Twitter verification mess

Eli Lilly shares fell after pranksters using Twitter Blue impersonated it and made a surprising claim—and this might be just the beginning.

The Independent UK

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.